Anorexia nervosa, bulimia, and binge eating disorder are emerging targets in psychedelic research. Anorexia has one of the highest mortality rates of any psychiatric condition and responds poorly to existing treatments, making it a priority for novel approaches. Psilocybin trials at Johns Hopkins and University of California are in early phases, with promising signals around body image and psychological flexibility.
MDMA-assisted therapy is being explored for eating disorders given the high co-occurrence with trauma. Researchers hypothesize that MDMA's ability to reduce fear while increasing empathy and openness could help patients address the underlying trauma and distorted cognitions that drive disordered eating.
What clinical research has shown for Eating Disorders, with citations to the studies behind each finding
In a phase 1 open-label feasibility study of 10 women with anorexia nervosa, a single 25 mg dose of psilocybin with psychological support was safe and well tolerated, and participants found it meaningful. The study was not designed to prove the treatment works — larger controlled trials are the next step.
These summaries are for general education, not medical advice. Most psychedelic therapies remain investigational and are not yet approved — always consult a qualified clinician.
There are currently no clinical trials for Eating Disorders in our database.